Prognostic value of the preoperative prognostic nutritional and systemic immunoinflammatory indexes in patients with colorectal cancer

Prognostic value of the preoperative prognostic nutritional and systemic immunoinflammatory indexes in patients with colorectal cancer | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Prognostic value of the preoperative prognostic nutritional and systemic immunoinflammatory indexes in patients with colorectal cancer Haifeng Li, Wei Sun, Shengfeng Fu, Junfeng Wang, Bin Jin, Shuo Zhang, and 3 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4712641/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 05 Mar, 2025 Read the published version in BMC Cancer → Version 1 posted 17 You are reading this latest preprint version Abstract Background Colorectal cancer (CRC) is a common malignant tumor of the digestive tract. Although many prognostic indicators are currently available, it remains unclear which indicators are the most beneficial for patients with CRC. Therefore, there is a critical need to identify a simple, convenient and accurate prognostic indicator. Purpose To investigate the clinical significance of the systemic immune-inflammation index (SII) and prognostic nutritional index (PNI) as prognostic indicators for the survival of patients with CRC. Methods The clinical data of CRC patients admitted to the general surgery ward of Taizhou People's Hospital affiliated to Nanjing Medical University from January 2015 to January 2018 were retrospectively analyzed. Two prognostic indicators (SII and PNI) were compared to evaluate their prognostic value in CRC patients. Results Based on these variables, we constructed a LASSO prediction model. The AUC value and 95% CI of the training group were 0.917 (0.858–0.976) compared to 0.932 (0.846–1.000) in the validation group. We found that CEA > 5 ng/mL, tumor stage, pathological type, postoperative complications, and PNI were associated with the five-year survival rate of CRC patients. Receiver Operating Characteristic Curves (ROC) were drawn to assess the prediction accuracy of the model. The AUC and 95% CI of the training group were 0.913 (0.854–0.972), while the AUC and 95% CI of the validation group were 0.954 (0.899–1.000). Conclusions PNI is an independent risk factor for postoperative complications associated with CRC and a powerful tool for predicting survival outcomes in CRC patients. colorectal cancer systemic immune-inflammation index prognostic nutritional index prognosis Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Figure 8 Figure 9 1. Introduction Colorectal cancer (CRC) is one of the most common gastrointestinal malignancies in the world, with 800,000 deaths reported globally every year [ 1 , 2 ] . In 2020, approximately 19.3 million new cancer cases and nearly 10 million cancer deaths worldwide were reported [ 3 ] . The main risk factor for CRC is age [ 4 ] , although other inherent risk factors such as inflammatory bowel disease and Crohn's disease have also been identified as important risk factors [ 5 ] . The global increase in CRC can be attributed to an increasingly aging population, adverse modern dietary habits, and an association with increased risk factors such as smoking, physical inactivity, and obesity [ 6 – 10 ] . The prognostic nutritional index (PNI) refers to the use of serum albumin and peripheral blood level lymphocyte counts, and was originally used to predict preoperative nutritional status by assessing postoperative complications in patients undergoing surgery [ 11 ] . Recent studies have shown that the PNI has high accuracy in predicting various cancers [ 12 ] . Immune system function plays a crucial role in tumor efficacy, and serum albumin and lymphocyte levels are important indicators of immune system function [ 13 ] . Thus, the PNI is a comprehensive reflection of the nutritional and immune status of patients and is closely associated with the body's ability to clear tumor cells and reduce local recurrence [ 14 ] . The systemic immune-inflammation index (SII) is a valuable prognostic indicator that reflects the local immune response and systemic inflammation of the whole body [ 15 ] . The SII was first proposed by Hu et al in 2014 and has since been extensively studied [ 16 ] . The SII is often used as a predictor of mortality in cancer patients because higher SII values are associated with an increased risk of death [ 17 ] . In patients with tumors, both pro-tumor and anti-tumor factors are induced in the body, including increased neutrophil and platelet levels, decreased lymphocyte levels, and increased SII values [ 18 ] . In recent years, the application of the SII has expanded, such that it can also be used to predict the severity of various diseases and the effects of different treatments [ 19 ] . Carcinoembryonic antigen (CEA) and carbohydrate antigen 19 − 9 (CA19-9) are well-established tumor markers that are present at elevated levels in the serum of patients with various gastrointestinal tumors or in cases where tumor metastasis has already occurred [ 20 , 21 ] . Although CEA and CA19-9 can be used to monitor CRC patients, abnormal changes may also occur in colorectal polyps, indicating that these markers lack specificity and sensitivity [ 22 , 23 ] . Tumor Protein p53 ( TP53 ) is the most commonly mutated gene in humans with CRC [ 24 ] . TP53 is a key tumor suppressor, and loss of TP53 function is often a prerequisite for cancer development [ 25 ] . However, the diagnosis and treatment of tumor patients harboring TP53 mutations is expensive and places a financial burden on the patients and their families. Therefore, there is a critical need to find a simple, inexpensive and reliable prognostic index. Patients with malignant tumors often have cachexia, severe malnutrition and chronic inflammatory stimulation, which have negative effects on the treatment of patients. Therefore, the aim of this study was to examine further the prognostic value of the SII and PNI in CRC patients before and/or before treatment. 2. Methods 2.1 Study participants This study was approved by the Ethics Committee of Taizhou People's Hospital Affiliated to Nanjing Medical University and was strictly screened according to the inclusion and exclusion criteria. The clinical data of patients with CRC admitted to the general surgery ward of Taizhou People's Hospital Affiliated to Nanjing Medical University (Taizhou, China) from January 2018 to December 2023 were retrospectively collected. The inclusion criteria included: (1) aged 18–80 years old; (2) CRC was diagnosed after biopsy; (3) no other forms of treatment such as radiotherapy or chemotherapy were received after diagnosis; (4) written informed consent of the patient and their family was obtained; and (5) the complete medical records and follow-up data of patients were available. The exclusion criteria included: (1) CRC patients with tumors at other sites; (2) CRC patients with a severe bleeding tendency; (3) CRC patients with serious medical diseases; (4) CRC patients that had undergone other treatment options; and (5) patients with incomplete medical records. 2.2 Data collection General information was collected including the patient's age, sex, height, weight, Body Mass Index (BMI), hypertension, diabetes, tumor location, surgical method, preoperative albumin, preoperative lymphocytes, preoperative neutrophils, preoperative platelets, preoperative monocytes, preoperative white blood cells, preoperative hemoglobin, CEA, CA125, CA19-9, maximum tumor diameter, tumor stage, the presence of lymph node metastasis, pathological type, five-year overall survival (OS), PNI, SII and other clinical data. Patients were followed up through outpatient clinics and telephone calls. A total of 221 CRC patients were followed. By December 2023, data regarding the survival status of patients diagnosed with CRC after surgical treatment in our hospital and five-year follow-up data were obtained. The SII value was calculated as follows: SII = platelet count (P) × neutrophil count (N)/lymphocyte count (L). The PNI value was calculated as follows: PNI = neutrophil count (N)/lymphocyte count (L). 2.3 Statistical analysis Key variables were screened using LASSO and a LASSO prediction model was developed based on the selected variables. Next, COX regression analysis was performed on the selected variables. The validity of the LASSO-Cox regression model was assessed by generating receiver operating characteristic (ROC) curves on the prediction models of the training and validation groups. P < 0.05 indicated that differences were statistically significant. 3. Results 3.1 Baseline characteristics of five-year survival in patients with CRC First, we examined the potential factors associated with five-year survival or death in CRC patients to identify the risk factors associated with mortality in CRC patients. As shown in Table 1, CEA > 5 ng/mL (P = 0.001), tumor stage (P = 0.001), lymph node metastasis (P = 0.001), pathological type (P = 0.001), postoperative complications (P = 0.001), intraoperative bleeding > 100 ml (P = 0.035), intraoperative blood transfusion (P = 0.004), leukocyte (P = 0.028), albumin (P = 0.028), prealbumin (P = 0.001), lymphocytes (P = 0.001), PNI (P = 0.001) and SII (P = 0.001) were significantly different between the surviving and deceased groups. Therefore, we hypothesized that these risk factors were associated with the five-year survival of CRC patients. 3.2 Construction of a five-year survival prediction model for patients with CRC The variables were screened using the LASSO regression model (Fig. 1, Fig. 2 and Table 2). A death prediction model was constructed by randomly assigning the total population to a training group consisting of 70% of the patients (159 cases) and a validation group consisting of 30% of the patients (62 cases). The training group was set up to predict the model, while the validation group was used for validation. The LASSO model for screening key variables was evaluated using ROC curves with the training group ROC curve shown in Fig. 3 and that of the validation group shown in Fig. 4. We found that the AUC values and 95% CI were 0.917 (0.858–0.976) in the training group and 0.932 (0.846–1.000) in the validation group, suggesting that the LASSO model had an excellent ability to screen for key variables. 3.3 Survival analysis of prognosis of patients with CRC Survival analysis was performed on the selected key variables. We found that CEA (P = 0.006), tumor stage (P = 0.016), pathological type (P = 0.033), postoperative complications (P = 0.047) and PNI (P = 0.000) were all significant (Table 3). 3.4 Establishment and efficacy evaluation of a prognostic predictive model for CRC The key variables (CEA, tumor stage, pathological type, complications and PNI) were selected by survival analysis and a nomogram was constructed. As shown in Fig. 5 , the nomogram had certain clinical practicability. Each predicted risk factor was given a corresponding score. A total score was then calculated for each patient based on the predicted risk factor score for each of the patient’s risk factors. The numbers corresponding to the total score were plotted vertically to obtain the predicted survival rates of CRC patients at 12, 36 and 60 months. The predictive ability of the nomogram was further evaluated by drawing ROC curves. The ROC curves of the training group predicted model and validation group predicted model are shown in Fig. 6 and Fig. 7, respectively. The AUC value and 95% CI of the training group were 0.913 (0.854–0.972) compared to 0.954 (0.899–1.000) in the validation group. These results suggested that the nomogram model was good for predicting the five-year survival in CRC patients. Finally, the correction curve was drawn, and revealed that the actual situation and prediction results were in high agreement, indicating that the predictive model was accurate (Figs. 8–9). 4. Discussion There is growing evidence that the SII and PNI, which reflect systemic inflammation and nutritional status, can reflect the relationship between host inflammation and immune status, and accurately predict the prognosis of cancer patients [ 26 ] . However, the relationship between the PNI, SII and clinical outcomes in CRC patients remains unclear. The primary objective of this study was to assess the prognostic value of the SII and PNI in CRC patients undergoing surgical removal. Our results show that among the risk factors associated with five-year survival or death in CRC patients, the PIN and SII are closely associated with mortality in CRC patients. Survival analysis revealed that CEA, tumor stage, pathological type, postoperative complications and PNI were significant risk factors for CRC patients, with PNI showing the highest significance. The nutritional and inflammatory status of the body has been shown to play an important role in the occurrence, development and prognosis of tumors. Previous studies have confirmed that preoperative hypoalbuminemia is closely related to postoperative morbidity and mortality, as well as a poor survival rate after tumor surgery [ 27 ] . Serum albumin levels are important independent biomarkers for a wide range of human diseases, including cancer [ 28 ] . Interestingly, albumin has been shown to display active tumor targeting effects through its interactions with GP60 and secreted protein acidic and rich in cysteine in tumor-associated endothelial cells and the tumor microenvironment [ 29 ] . The prognostic value of a pretreatment PNI in patients with lung cancer was systematically evaluated in a 2018 meta-analysis. A low pretreatment PNI was found to be closely associated with poor OS in lung cancer patients, and a predictor of poor survival [ 30 ] . Similarly, Zhang et al. examined the relationship between the PNI and OS, disease free survival and progression free survival (PFS) in breast cancer patients receiving clinical treatment. High PNI values were found to be a favorable independent predictor of prolonged OS and PFS in breast cancer patients after clinical treatment, and the PNI was significantly correlated with the prognosis of breast cancer patients [ 31 ] . A study evaluating the relationship between preoperative SII and the prognosis and clinicopathological features of bladder cancer in 7087 patients found that preoperative SII elevation was associated with poor tumor differentiation, high tumor stage, lymph node involvement, and tumor size ≥ 3 cm. Moreover, preoperative SII elevation was significantly associated with poor survival outcomes and adverse pathological features [ 32 ] . The SII, as an inflammatory indicator, has been identified as a prognostic biomarker in various diseases including acute kidney injury, fatty liver, hyperlipidemia, ischemic stroke, Alzheimer's disease and cerebral hemorrhage [ 33 – 37 ] . In recent years, increasing evidence has suggested that the interaction between tumor cells and platelets is a prerequisite for the successful transmission of blood metastasis [ 38 ] . Platelets stimulate the proliferation of cancer cells by releasing a variety of cytokines and chemokines, as well as accelerate tumor angiogenesis through various angiogenic regulatory factors, thereby playing a crucial role in the growth and metastasis of cancer cells [ 39 ] . Zhang et al. demonstrated that cancer cells can be reprogrammed to a metastatic state by acquiring platelet mitochondria via the PINK1/Parkin-Mfn2 signaling pathway. In addition, platelet mitochondria regulate the GSH/GSSG ratio and reactive oxygen species of tumor cells, promoting lung metastasis of osteosarcoma [ 40 ] . Neutrophils are the most abundant myeloid cells in human blood and are important regulators of cancer [ 41 ] . External stimulation of the tumor microenvironment can trigger the accumulation of tumor-associated neutrophils in local areas and switch between anti-tumor and pro-tumor phenotypes [ 42 ] . Anti-tumor neutrophils kill tumor cells directly through cytotoxic effects, as well as indirectly through the activation of adaptive immune responses. In contrast, the pro-tumor phenotype of neutrophils may be related to cell proliferation, angiogenesis, and immunosuppression in the tumor microenvironment [ 43 ] . There are several limitations associated with the analytical process of this retrospective study. First, subjectivity in the collection of CRC patient data may have contributed to biases in our findings. Secondly, the influencing factors included in our study are not comprehensive. Third, this retrospective study is a single-center study that includes a relatively small number of patients, which may affect the accuracy of our results. Future studies that incorporate more patients from multiple centers and a comprehensive risk factor analysis are the next step to carry out survival and related risk factor analyses of CRC patients to better serve clinicians and patients. 5. Conclusion The PNI is a simple and feasible indicator for predicting CRC, and can therefore be used as an effective prognostic indicator for postoperative survival, which will benefit clinicians in their decision making processes regarding individual patient treatment strategies and medication plans. Declarations Data availability statement The raw data supporting the findings of this study will be made available by the authors without undue reservation. Ethics statement This study involving human participants was approved by the Medical Ethics Committee of the Taizhou People's Hospital Affiliated to Nanjing Medical University (Taizhou, China). The ethics committee waived the requirement for informed consent from patients. Conflict of interest statement The authors declare that they have no conflicts of interest. Funding sources This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Author Contribution HGQ and QYZ conceived and designed the experiments and supervised the study. SFF collected the data. WS and JFW analysed and interpreted the data. BJ and SZ applied for approval of ethics. HFL wrote the manuscript and supervised the study. All authors read and approved the final manuscript for publication. Acknowledgements We appreciate the data collectors, supervisors, and study participants for their courtesy and cooperation, without whom the study would not have been possible to complete the entire data collection process. We alao thank International Science Editing ( http://www.internationalscienceediting.com ) for editing this manuscript. References Lannagan TR, Jackstadt R, Leedham SJ, et al. Advances in colon cancer research: in vitro and animal models[J]. Curr Opin Genet Dev. 2021;66:50–6. Colon Cancer[J]. Am Fam Physician. 2018;97(10):Online. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin. 2021;71(3):209–49. Baidoun F, Elshiwy K, Elkeraie Y, et al. Colorectal Cancer Epidemiology: Recent Trends and Impact on Outcomes[J]. Curr Drug Targets. 2021;22(9):998–1009. Su Y, Yuan Y, Feng S, et al. High frequency stimulation induces sonic hedgehog release from hippocampal neurons[J]. Sci Rep. 2017;7:43865. Breakwell GM. Are you stressed out?[J]. Am J Nurs. 1990;90(8):31–3. Bai X, Wei H, Liu W, et al. Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites[J]. Gut. 2022;71(12):2439–50. Motsuku L, Chen WC, Muchengeti MM, et al. Colorectal cancer incidence and mortality trends by sex and population group in South Africa: 2002–2014[J]. BMC Cancer. 2021;21(1):129. Bradbury KE, Murphy N, Key TJ. Diet and colorectal cancer in UK Biobank: a prospective study[J]. Int J Epidemiol. 2020;49(1):246–58. Bardou M, Barkun AN, Martel M. Obesity and colorectal cancer[J]. Gut. 2013;62(6):933–47. Mohri Y, Inoue Y, Tanaka K, et al. Prognostic nutritional index predicts postoperative outcome in colorectal cancer[J]. World J Surg. 2013;37(11):2688–92. Shen F, Ma Y, Guo W, et al. Prognostic Value of Geriatric Nutritional Risk Index for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis[J]. Lung. 2022;200(5):661–9. Ishiguro T, Aoyama T, Ju M, et al. Prognostic Nutritional Index as a Predictor of Prognosis in Postoperative Patients With Gastric Cancer[J]. Vivo. 2023;37(3):1290–6. Zhang L, Ma W, Qiu Z, et al. Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors[J]. Front Immunol. 2023;14:1219929. Huang H, Liu Q, Zhu L, et al. Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Patients with Cervical Cancer[J]. Sci Rep. 2019;9(1):3284. Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma[J]. Clin Cancer Res. 2014;20(23):6212–22. He L, Xie X, Xue J, et al. Association of the systemic immune-inflammation index with all-cause mortality in patients with arteriosclerotic cardiovascular disease[J]. Front Cardiovasc Med. 2022;9:952953. Liu B, Wang J, Li YY, et al. The association between systemic immune-inflammation index and rheumatoid arthritis: evidence from NHANES 1999–2018[J]. Arthritis Res Ther. 2023;25(1):34. Xie R, Liu X, Wu H, et al. Associations between systemic immune-inflammation index and abdominal aortic calcification: Results of a nationwide survey[J]. Nutr Metab Cardiovasc Dis. 2023;33(7):1437–43. Ushigome M, Shimada H, Miura Y, et al. Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA[J]. Int J Clin Oncol. 2020;25(4):622–32. Liu JM, Wang YY, Liu W, et al. Preoperative CA19-9: a competitive predictor of recurrence in patients with colorectal cancer liver metastases after hepatectomy[J]. Int J Colorectal Dis. 2021;36(4):767–78. Galli C, Basso D, Plebani M. CA 19 – 9: handle with care[J]. Clin Chem Lab Med. 2013;51(7):1369–83. Yu D, An G, Yao J. Lymphocyte-to-monocyte ratio combined with CA19-9 for predicting postoperative recurrence of colorectal cancer in patients with diabetes[J]. J Clin Lab Anal. 2021;35(9):e23944. Giannakis M, Mu XJ, Shukla SA, et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma[J]. Cell Rep. 2016;15(4):857–65. Zhang C, Liu J, Xu D, et al. Gain-of-function mutant p53 in cancer progression and therapy[J]. J Mol Cell Biol. 2020;12(9):674–87. Kubota K, Ito R, Narita N, et al. Utility of prognostic nutritional index and systemic immune-inflammation index in oral cancer treatment[J]. BMC Cancer. 2022;22(1):368. Rudnik-Jansen I, Howard KA. FcRn expression in cancer: Mechanistic basis and therapeutic opportunities[J]. J Control Release. 2021;337:248–57. Jeng LB, Chan WL, Teng CF. Prognostic Significance of Serum Albumin Level and Albumin-Based Mono- and Combination Biomarkers in Patients with Hepatocellular Carcinoma[J]. Cancers (Basel), 2023,15(4). Paul M, Itoo AM, Ghosh B, et al. Current trends in the use of human serum albumin for drug delivery in cancer[J]. Expert Opin Drug Deliv. 2022;19(11):1449–70. Wang Z, Wang Y, Zhang X, et al. Pretreatment prognostic nutritional index as a prognostic factor in lung cancer: Review and meta-analysis[J]. Clin Chim Acta. 2018;486:303–10. Zhang X, Liu Y, Mu D. Influence of Prognostic Nutritional Index on the Surveillance After Surgery-Based Systematic Therapy for Breast Cancer[J]. Am Surg. 2023;89(12):6157–71. Li J, Cao D, Huang Y, et al. The Prognostic and Clinicopathological Significance of Systemic Immune-Inflammation Index in Bladder Cancer[J]. Front Immunol. 2022;13:865643. Mahemuti N, Jing X, Zhang N et al. Association between Systemic Immunity-Inflammation Index and Hyperlipidemia: A Population-Based Study from the NHANES (2015–2020)[J]. Nutrients, 2023,15(5). Thakur S, Dhapola R, Sarma P, et al. Neuroinflammation in Alzheimer's Disease: Current Progress in Molecular Signaling and Therapeutics[J]. Inflammation. 2023;46(1):1–17. Guo W, Song Y, Sun Y, et al. Systemic immune-inflammation index is associated with diabetic kidney disease in Type 2 diabetes mellitus patients: Evidence from NHANES 2011–2018[J]. Front Endocrinol (Lausanne). 2022;13:1071465. Song Y, Guo W, Li Z, et al. Systemic immune-inflammation index is associated with hepatic steatosis: Evidence from NHANES 2015–2018[J]. Front Immunol. 2022;13:1058779. Wang RH, Wen WX, Jiang ZP, et al. The clinical value of neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR) and systemic inflammation response index (SIRI) for predicting the occurrence and severity of pneumonia in patients with intracerebral hemorrhage[J]. Front Immunol. 2023;14:1115031. Geranpayehvaghei M, Dabirmanesh B, Khaledi M, et al. Cancer-associated-platelet-inspired nanomedicines for cancer therapy[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021;13(5):e1702. Sabrkhany S, Kuijpers M, Oude EM, et al. Platelets as messengers of early-stage cancer[J]. Cancer Metastasis Rev. 2021;40(2):563–73. Zhang W, Zhou H, Li H, et al. Cancer cells reprogram to metastatic state through the acquisition of platelet mitochondria[J]. Cell Rep. 2023;42(9):113147. Hedrick CC, Malanchi I. Neutrophils in cancer: heterogeneous and multifaceted[J]. Nat Rev Immunol. 2022;22(3):173–87. Adrover JM, McDowell S, He XY, et al. NETworking with cancer: The bidirectional interplay between cancer and neutrophil extracellular traps[J]. Cancer Cell. 2023;41(3):505–26. Que H, Fu Q, Lan T, et al. Tumor-associated neutrophils and neutrophil-targeted cancer therapies[J]. Biochim Biophys Acta Rev Cancer. 2022;1877(5):188762. Tables Tables 1 to 3 are available in the Supplementary Files section. Additional Declarations No competing interests reported. Supplementary Files Table1.docx Table2.docx Table3.docx Cite Share Download PDF Status: Published Journal Publication published 05 Mar, 2025 Read the published version in BMC Cancer → Version 1 posted Editorial decision: Revision requested 11 Feb, 2025 Reviews received at journal 11 Feb, 2025 Reviewers agreed at journal 11 Feb, 2025 Reviewers agreed at journal 11 Feb, 2025 Reviewers agreed at journal 22 Jan, 2025 Reviews received at journal 21 Jan, 2025 Reviewers agreed at journal 21 Jan, 2025 Reviewers agreed at journal 20 Jan, 2025 Reviewers agreed at journal 19 Jan, 2025 Reviewers agreed at journal 17 Jan, 2025 Reviewers agreed at journal 17 Jan, 2025 Reviewers agreed at journal 17 Jan, 2025 Reviewers invited by journal 17 Aug, 2024 Editor invited by journal 12 Jul, 2024 Editor assigned by journal 10 Jul, 2024 Submission checks completed at journal 10 Jul, 2024 First submitted to journal 09 Jul, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4712641","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":333054922,"identity":"730dc7d0-90b2-4249-ac44-134e83e94365","order_by":0,"name":"Haifeng Li","email":"","orcid":"","institution":"The Affiliated Taizhou People’s Hospital of Nanjing Medical University, Nanjing Medical University","correspondingAuthor":false,"prefix":"","firstName":"Haifeng","middleName":"","lastName":"Li","suffix":""},{"id":333054923,"identity":"e5966f23-cf6a-491d-a574-9bb38fb5292e","order_by":1,"name":"Wei Sun","email":"","orcid":"","institution":"Hefei high-tech cardiovascular hospital","correspondingAuthor":false,"prefix":"","firstName":"Wei","middleName":"","lastName":"Sun","suffix":""},{"id":333054924,"identity":"be5988d6-d5fd-413b-96f4-4ba2aff1f23e","order_by":2,"name":"Shengfeng Fu","email":"","orcid":"","institution":"The Affiliated Taizhou People’s Hospital of Nanjing Medical University, Nanjing Medical University","correspondingAuthor":false,"prefix":"","firstName":"Shengfeng","middleName":"","lastName":"Fu","suffix":""},{"id":333054925,"identity":"e59a97e6-3a9a-42da-9af0-707c6bb78b85","order_by":3,"name":"Junfeng Wang","email":"","orcid":"","institution":"The Affiliated Taizhou People’s Hospital of Nanjing Medical University, Nanjing Medical University","correspondingAuthor":false,"prefix":"","firstName":"Junfeng","middleName":"","lastName":"Wang","suffix":""},{"id":333054926,"identity":"66dc5461-3b5f-41fa-8a68-0d7921b35699","order_by":4,"name":"Bin Jin","email":"","orcid":"","institution":"The Affiliated Taizhou People’s Hospital of Nanjing Medical University, Nanjing Medical University","correspondingAuthor":false,"prefix":"","firstName":"Bin","middleName":"","lastName":"Jin","suffix":""},{"id":333054927,"identity":"8325b349-2083-4ad4-a39d-275a2099bba7","order_by":5,"name":"Shuo Zhang","email":"","orcid":"","institution":"The Affiliated Taizhou People’s Hospital of Nanjing Medical University, Nanjing Medical University","correspondingAuthor":false,"prefix":"","firstName":"Shuo","middleName":"","lastName":"Zhang","suffix":""},{"id":333054928,"identity":"780a5a7c-02ad-473b-bc2d-12ed9b5402bd","order_by":6,"name":"Yujun Liu","email":"","orcid":"","institution":"The Affiliated Taizhou People’s Hospital of Nanjing Medical University, Nanjing Medical University","correspondingAuthor":false,"prefix":"","firstName":"Yujun","middleName":"","lastName":"Liu","suffix":""},{"id":333054929,"identity":"834b4a9e-171b-45bb-8aa5-32d6a5372af8","order_by":7,"name":"Qinyang Zhang","email":"","orcid":"","institution":"The First Affliated Hospital of Chongqing Medical University","correspondingAuthor":false,"prefix":"","firstName":"Qinyang","middleName":"","lastName":"Zhang","suffix":""},{"id":333054930,"identity":"db5fdcfa-5cf7-469f-a808-b910ace234a0","order_by":8,"name":"Honggang Wang","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA90lEQVRIiWNgGAWjYJACZjjrAwMbmJYgWgvjDJK1MPNAGXi1GBw/e/h1QcUdu/nuQIbtDr5ogwPMB2/zMNjl4dRyJi/NesaZZ8kbQYzcM2y5Gw6wJVvzMCQX49JidiDHzJi37XCyYQOQkdsG0sJjJs3DcCCxAZeW82+gWvqBDEuwFv5v+LXcyDF+DNRiJy8BZDBCbGHDq8X+xhszZp4zhxMMJN6YMfYCtcw8zGZsOccgGacWyf4c4888FYft5YGMDz/bjuX2HW9+eONNhR1OLUDABoqFxA0HwIxj0GgywK0eCJg/gBwo3wBm1OBVOgpGwSgYBSMTAAAfzlsH/JdLcAAAAABJRU5ErkJggg==","orcid":"","institution":"Nanjing Medical University","correspondingAuthor":true,"prefix":"","firstName":"Honggang","middleName":"","lastName":"Wang","suffix":""}],"badges":[],"createdAt":"2024-07-09 14:04:46","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4712641/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4712641/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s12885-025-13828-3","type":"published","date":"2025-03-05T15:58:43+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":62157046,"identity":"04623310-12b6-42ec-8e44-065a4a8afc53","added_by":"auto","created_at":"2024-08-09 21:14:35","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":10392,"visible":true,"origin":"","legend":"\u003cp\u003eThe LASSO-Cox regression model screening parameters\u003c/p\u003e","description":"","filename":"Fig1.png","url":"https://assets-eu.researchsquare.com/files/rs-4712641/v1/833da4a65e9edb13ffef3b41.png"},{"id":62157731,"identity":"d1bb9d95-dd7f-423c-bd74-1a8ea374a7b6","added_by":"auto","created_at":"2024-08-09 21:22:35","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":7332,"visible":true,"origin":"","legend":"\u003cp\u003eThe LASSO-Cox regression model screening parameters\u003c/p\u003e","description":"","filename":"Fig2.png","url":"https://assets-eu.researchsquare.com/files/rs-4712641/v1/8ce05d51dab57de612743a08.png"},{"id":62157054,"identity":"ad97785b-db2f-46f1-b8ff-be1b224ecfa5","added_by":"auto","created_at":"2024-08-09 21:14:35","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":5763,"visible":true,"origin":"","legend":"\u003cp\u003eROC curves evaluating the LASSO screening models for key variables in both training and validation groups\u003c/p\u003e","description":"","filename":"Fig3.png","url":"https://assets-eu.researchsquare.com/files/rs-4712641/v1/9223a7976c908af0909f7ba7.png"},{"id":62157050,"identity":"b03d4b6c-fc07-4441-9fda-e31d2ca40d18","added_by":"auto","created_at":"2024-08-09 21:14:35","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":5690,"visible":true,"origin":"","legend":"\u003cp\u003eROC curves evaluating the LASSO screening models for key variables in both training and validation groups\u003c/p\u003e","description":"","filename":"Fig4.png","url":"https://assets-eu.researchsquare.com/files/rs-4712641/v1/f24fa89b23b7869637ccac8f.png"},{"id":62157047,"identity":"c5721943-617f-45fc-a96b-b4327c854d6f","added_by":"auto","created_at":"2024-08-09 21:14:35","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":13337,"visible":true,"origin":"","legend":"\u003cp\u003ePrediction of OS nomogram after laparoscopic radical resection of CRC\u003c/p\u003e","description":"","filename":"Fig5.png","url":"https://assets-eu.researchsquare.com/files/rs-4712641/v1/1bd4698a4f07528406e17213.png"},{"id":62157055,"identity":"90e78940-9505-4d93-b352-7ab28ce699d4","added_by":"auto","created_at":"2024-08-09 21:14:35","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":6352,"visible":true,"origin":"","legend":"\u003cp\u003eROC curve assessing the effectiveness of the prediction model\u003c/p\u003e","description":"","filename":"Fig6.png","url":"https://assets-eu.researchsquare.com/files/rs-4712641/v1/7339ace2cf1396f622e1b3d4.png"},{"id":62158213,"identity":"5eeeef4e-e1b5-4b1d-bfd5-5ff27a28e740","added_by":"auto","created_at":"2024-08-09 21:30:35","extension":"png","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":6070,"visible":true,"origin":"","legend":"\u003cp\u003eROC curve assessing the effectiveness of the prediction model\u003c/p\u003e","description":"","filename":"Fig7.png","url":"https://assets-eu.researchsquare.com/files/rs-4712641/v1/020a5e483f2fbc99c0a25935.png"},{"id":62157736,"identity":"5c22892a-312e-4e4a-abad-59696dfb9b36","added_by":"auto","created_at":"2024-08-09 21:22:35","extension":"png","order_by":8,"title":"Figure 8","display":"","copyAsset":false,"role":"figure","size":5185,"visible":true,"origin":"","legend":"\u003cp\u003eCorrection curve evaluating the predicted and actual situation\u003c/p\u003e","description":"","filename":"Fig8.png","url":"https://assets-eu.researchsquare.com/files/rs-4712641/v1/d2f58eea9829895f8157b806.png"},{"id":62157056,"identity":"a9d142b8-83ff-4871-9f0a-2ac8f3b2346c","added_by":"auto","created_at":"2024-08-09 21:14:35","extension":"png","order_by":9,"title":"Figure 9","display":"","copyAsset":false,"role":"figure","size":5029,"visible":true,"origin":"","legend":"\u003cp\u003eCorrection curve evaluating the predicted and actual situation\u003c/p\u003e","description":"","filename":"Fig9.png","url":"https://assets-eu.researchsquare.com/files/rs-4712641/v1/b4a723c46bcd29035e943fb0.png"},{"id":78190693,"identity":"57cbf682-7acc-437e-b632-c58d861d2375","added_by":"auto","created_at":"2025-03-10 19:50:37","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":766054,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4712641/v1/51cb58dd-462b-4eb5-bc1a-205b19559455.pdf"},{"id":62157732,"identity":"a7cdb8a3-c5d7-4774-9bb5-4bbe2d7f6345","added_by":"auto","created_at":"2024-08-09 21:22:35","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":15403,"visible":true,"origin":"","legend":"","description":"","filename":"Table1.docx","url":"https://assets-eu.researchsquare.com/files/rs-4712641/v1/f117293174f9ba695cb2653d.docx"},{"id":62157733,"identity":"372fdfa4-7e51-4cb5-9e4c-f878a657da6b","added_by":"auto","created_at":"2024-08-09 21:22:35","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":14498,"visible":true,"origin":"","legend":"","description":"","filename":"Table2.docx","url":"https://assets-eu.researchsquare.com/files/rs-4712641/v1/043676caeb12ed87acd78939.docx"},{"id":62157734,"identity":"9c8965a2-3ce5-419b-9b26-61c744ac9f2f","added_by":"auto","created_at":"2024-08-09 21:22:35","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":12355,"visible":true,"origin":"","legend":"","description":"","filename":"Table3.docx","url":"https://assets-eu.researchsquare.com/files/rs-4712641/v1/7d2398094ee1b2908a792b60.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"Prognostic value of the preoperative prognostic nutritional and systemic immunoinflammatory indexes in patients with colorectal cancer","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eColorectal cancer (CRC) is one of the most common gastrointestinal malignancies in the world, with 800,000 deaths reported globally every year\u003csup\u003e[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]\u003c/sup\u003e. In 2020, approximately 19.3\u0026nbsp;million new cancer cases and nearly 10\u0026nbsp;million cancer deaths worldwide were reported\u003csup\u003e[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]\u003c/sup\u003e. The main risk factor for CRC is age\u003csup\u003e[\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]\u003c/sup\u003e, although other inherent risk factors such as inflammatory bowel disease and Crohn's disease have also been identified as important risk factors\u003csup\u003e[\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]\u003c/sup\u003e. The global increase in CRC can be attributed to an increasingly aging population, adverse modern dietary habits, and an association with increased risk factors such as smoking, physical inactivity, and obesity\u003csup\u003e[\u003cspan additionalcitationids=\"CR7 CR8 CR9\" citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eThe prognostic nutritional index (PNI) refers to the use of serum albumin and peripheral blood level lymphocyte counts, and was originally used to predict preoperative nutritional status by assessing postoperative complications in patients undergoing surgery\u003csup\u003e[\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]\u003c/sup\u003e. Recent studies have shown that the PNI has high accuracy in predicting various cancers\u003csup\u003e[\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]\u003c/sup\u003e. Immune system function plays a crucial role in tumor efficacy, and serum albumin and lymphocyte levels are important indicators of immune system function\u003csup\u003e[\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]\u003c/sup\u003e. Thus, the PNI is a comprehensive reflection of the nutritional and immune status of patients and is closely associated with the body's ability to clear tumor cells and reduce local recurrence\u003csup\u003e[\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eThe systemic immune-inflammation index (SII) is a valuable prognostic indicator that reflects the local immune response and systemic inflammation of the whole body\u003csup\u003e[\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]\u003c/sup\u003e. The SII was first proposed by Hu et al in 2014 and has since been extensively studied\u003csup\u003e[\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]\u003c/sup\u003e. The SII is often used as a predictor of mortality in cancer patients because higher SII values are associated with an increased risk of death\u003csup\u003e[\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]\u003c/sup\u003e. In patients with tumors, both pro-tumor and anti-tumor factors are induced in the body, including increased neutrophil and platelet levels, decreased lymphocyte levels, and increased SII values\u003csup\u003e[\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]\u003c/sup\u003e. In recent years, the application of the SII has expanded, such that it can also be used to predict the severity of various diseases and the effects of different treatments\u003csup\u003e[\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eCarcinoembryonic antigen (CEA) and carbohydrate antigen 19\u0026thinsp;\u0026minus;\u0026thinsp;9 (CA19-9) are well-established tumor markers that are present at elevated levels in the serum of patients with various gastrointestinal tumors or in cases where tumor metastasis has already occurred\u003csup\u003e[\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e, \u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]\u003c/sup\u003e. Although CEA and CA19-9 can be used to monitor CRC patients, abnormal changes may also occur in colorectal polyps, indicating that these markers lack specificity and sensitivity\u003csup\u003e[\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e, \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]\u003c/sup\u003e. Tumor Protein p53 (\u003cem\u003eTP53\u003c/em\u003e) is the most commonly mutated gene in humans with CRC\u003csup\u003e[\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]\u003c/sup\u003e. \u003cem\u003eTP53\u003c/em\u003e is a key tumor suppressor, and loss of \u003cem\u003eTP53\u003c/em\u003e function is often a prerequisite for cancer development\u003csup\u003e[\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]\u003c/sup\u003e. However, the diagnosis and treatment of tumor patients harboring \u003cem\u003eTP53\u003c/em\u003e mutations is expensive and places a financial burden on the patients and their families. Therefore, there is a critical need to find a simple, inexpensive and reliable prognostic index.\u003c/p\u003e \u003cp\u003ePatients with malignant tumors often have cachexia, severe malnutrition and chronic inflammatory stimulation, which have negative effects on the treatment of patients. Therefore, the aim of this study was to examine further the prognostic value of the SII and PNI in CRC patients before and/or before treatment.\u003c/p\u003e"},{"header":"2. Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e2.1 Study participants\u003c/h2\u003e \u003cp\u003e This study was approved by the Ethics Committee of Taizhou People's Hospital Affiliated to Nanjing Medical University and was strictly screened according to the inclusion and exclusion criteria. The clinical data of patients with CRC admitted to the general surgery ward of Taizhou People's Hospital Affiliated to Nanjing Medical University (Taizhou, China) from January 2018 to December 2023 were retrospectively collected.\u003c/p\u003e \u003cp\u003eThe inclusion criteria included: (1) aged 18\u0026ndash;80 years old; (2) CRC was diagnosed after biopsy; (3) no other forms of treatment such as radiotherapy or chemotherapy were received after diagnosis; (4) written informed consent of the patient and their family was obtained; and (5) the complete medical records and follow-up data of patients were available. The exclusion criteria included: (1) CRC patients with tumors at other sites; (2) CRC patients with a severe bleeding tendency; (3) CRC patients with serious medical diseases; (4) CRC patients that had undergone other treatment options; and (5) patients with incomplete medical records.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e2.2 Data collection\u003c/h2\u003e \u003cp\u003eGeneral information was collected including the patient's age, sex, height, weight, Body Mass Index (BMI), hypertension, diabetes, tumor location, surgical method, preoperative albumin, preoperative lymphocytes, preoperative neutrophils, preoperative platelets, preoperative monocytes, preoperative white blood cells, preoperative hemoglobin, CEA, CA125, CA19-9, maximum tumor diameter, tumor stage, the presence of lymph node metastasis, pathological type, five-year overall survival (OS), PNI, SII and other clinical data. Patients were followed up through outpatient clinics and telephone calls. A total of 221 CRC patients were followed. By December 2023, data regarding the survival status of patients diagnosed with CRC after surgical treatment in our hospital and five-year follow-up data were obtained.\u003c/p\u003e \u003cp\u003eThe SII value was calculated as follows: SII\u0026thinsp;=\u0026thinsp;platelet count (P) \u0026times; neutrophil count (N)/lymphocyte count (L). The PNI value was calculated as follows: PNI\u0026thinsp;=\u0026thinsp;neutrophil count (N)/lymphocyte count (L).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003e2.3 Statistical analysis\u003c/h2\u003e \u003cp\u003eKey variables were screened using LASSO and a LASSO prediction model was developed based on the selected variables. Next, COX regression analysis was performed on the selected variables. The validity of the LASSO-Cox regression model was assessed by generating receiver operating characteristic (ROC) curves on the prediction models of the training and validation groups. P\u0026thinsp;\u0026lt;\u0026thinsp;0.05 indicated that differences were statistically significant.\u003c/p\u003e \u003c/div\u003e"},{"header":"3. Results","content":"\u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003e3.1 Baseline characteristics of five-year survival in patients with CRC\u003c/h2\u003e \u003cp\u003eFirst, we examined the potential factors associated with five-year survival or death in CRC patients to identify the risk factors associated with mortality in CRC patients. As shown in Table\u0026nbsp;1, CEA\u0026thinsp;\u0026gt;\u0026thinsp;5 ng/mL (P\u0026thinsp;=\u0026thinsp;0.001), tumor stage (P\u0026thinsp;=\u0026thinsp;0.001), lymph node metastasis (P\u0026thinsp;=\u0026thinsp;0.001), pathological type (P\u0026thinsp;=\u0026thinsp;0.001), postoperative complications (P\u0026thinsp;=\u0026thinsp;0.001), intraoperative bleeding\u0026thinsp;\u0026gt;\u0026thinsp;100 ml (P\u0026thinsp;=\u0026thinsp;0.035), intraoperative blood transfusion (P\u0026thinsp;=\u0026thinsp;0.004), leukocyte (P\u0026thinsp;=\u0026thinsp;0.028), albumin (P\u0026thinsp;=\u0026thinsp;0.028), prealbumin (P\u0026thinsp;=\u0026thinsp;0.001), lymphocytes (P\u0026thinsp;=\u0026thinsp;0.001), PNI (P\u0026thinsp;=\u0026thinsp;0.001) and SII (P\u0026thinsp;=\u0026thinsp;0.001) were significantly different between the surviving and deceased groups. Therefore, we hypothesized that these risk factors were associated with the five-year survival of CRC patients.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003e3.2 Construction of a five-year survival prediction model for patients with CRC\u003c/h2\u003e \u003cp\u003eThe variables were screened using the LASSO regression model (Fig.\u0026nbsp;1, Fig.\u0026nbsp;2 and Table\u0026nbsp;2). A death prediction model was constructed by randomly assigning the total population to a training group consisting of 70% of the patients (159 cases) and a validation group consisting of 30% of the patients (62 cases).\u003c/p\u003e \u003cp\u003eThe training group was set up to predict the model, while the validation group was used for validation. The LASSO model for screening key variables was evaluated using ROC curves with the training group ROC curve shown in Fig.\u0026nbsp;3 and that of the validation group shown in Fig.\u0026nbsp;4. We found that the AUC values and 95% CI were 0.917 (0.858\u0026ndash;0.976) in the training group and 0.932 (0.846\u0026ndash;1.000) in the validation group, suggesting that the LASSO model had an excellent ability to screen for key variables.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003e3.3 Survival analysis of prognosis of patients with CRC\u003c/h2\u003e \u003cp\u003eSurvival analysis was performed on the selected key variables. We found that CEA (P\u0026thinsp;=\u0026thinsp;0.006), tumor stage (P\u0026thinsp;=\u0026thinsp;0.016), pathological type (P\u0026thinsp;=\u0026thinsp;0.033), postoperative complications (P\u0026thinsp;=\u0026thinsp;0.047) and PNI (P\u0026thinsp;=\u0026thinsp;0.000) were all significant (Table\u0026nbsp;3).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003e3.4 Establishment and efficacy evaluation of a prognostic predictive model for CRC\u003c/h2\u003e \u003cp\u003eThe key variables (CEA, tumor stage, pathological type, complications and PNI) were selected by survival analysis and a nomogram was constructed. As shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e5\u003c/span\u003e, the nomogram had certain clinical practicability. Each predicted risk factor was given a corresponding score. A total score was then calculated for each patient based on the predicted risk factor score for each of the patient\u0026rsquo;s risk factors. The numbers corresponding to the total score were plotted vertically to obtain the predicted survival rates of CRC patients at 12, 36 and 60 months.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eThe predictive ability of the nomogram was further evaluated by drawing ROC curves. The ROC curves of the training group predicted model and validation group predicted model are shown in Fig.\u0026nbsp;6 and Fig.\u0026nbsp;7, respectively. The AUC value and 95% CI of the training group were 0.913 (0.854\u0026ndash;0.972) compared to 0.954 (0.899\u0026ndash;1.000) in the validation group. These results suggested that the nomogram model was good for predicting the five-year survival in CRC patients. Finally, the correction curve was drawn, and revealed that the actual situation and prediction results were in high agreement, indicating that the predictive model was accurate (Figs.\u0026nbsp;8\u0026ndash;9).\u003c/p\u003e \u003c/div\u003e"},{"header":"4. Discussion","content":"\u003cp\u003eThere is growing evidence that the SII and PNI, which reflect systemic inflammation and nutritional status, can reflect the relationship between host inflammation and immune status, and accurately predict the prognosis of cancer patients\u003csup\u003e[\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]\u003c/sup\u003e. However, the relationship between the PNI, SII and clinical outcomes in CRC patients remains unclear. The primary objective of this study was to assess the prognostic value of the SII and PNI in CRC patients undergoing surgical removal. Our results show that among the risk factors associated with five-year survival or death in CRC patients, the PIN and SII are closely associated with mortality in CRC patients. Survival analysis revealed that CEA, tumor stage, pathological type, postoperative complications and PNI were significant risk factors for CRC patients, with PNI showing the highest significance.\u003c/p\u003e \u003cp\u003eThe nutritional and inflammatory status of the body has been shown to play an important role in the occurrence, development and prognosis of tumors. Previous studies have confirmed that preoperative hypoalbuminemia is closely related to postoperative morbidity and mortality, as well as a poor survival rate after tumor surgery\u003csup\u003e[\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e]\u003c/sup\u003e. Serum albumin levels are important independent biomarkers for a wide range of human diseases, including cancer\u003csup\u003e[\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e]\u003c/sup\u003e. Interestingly, albumin has been shown to display active tumor targeting effects through its interactions with GP60 and secreted protein acidic and rich in cysteine in tumor-associated endothelial cells and the tumor microenvironment\u003csup\u003e[\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e]\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eThe prognostic value of a pretreatment PNI in patients with lung cancer was systematically evaluated in a 2018 meta-analysis. A low pretreatment PNI was found to be closely associated with poor OS in lung cancer patients, and a predictor of poor survival\u003csup\u003e[\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e]\u003c/sup\u003e. Similarly, Zhang et al. examined the relationship between the PNI and OS, disease free survival and progression free survival (PFS) in breast cancer patients receiving clinical treatment. High PNI values were found to be a favorable independent predictor of prolonged OS and PFS in breast cancer patients after clinical treatment, and the PNI was significantly correlated with the prognosis of breast cancer patients\u003csup\u003e[\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e]\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eA study evaluating the relationship between preoperative SII and the prognosis and clinicopathological features of bladder cancer in 7087 patients found that preoperative SII elevation was associated with poor tumor differentiation, high tumor stage, lymph node involvement, and tumor size\u0026thinsp;\u0026ge;\u0026thinsp;3 cm. Moreover, preoperative SII elevation was significantly associated with poor survival outcomes and adverse pathological features\u003csup\u003e[\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]\u003c/sup\u003e. The SII, as an inflammatory indicator, has been identified as a prognostic biomarker in various diseases including acute kidney injury, fatty liver, hyperlipidemia, ischemic stroke, Alzheimer's disease and cerebral hemorrhage\u003csup\u003e[\u003cspan additionalcitationids=\"CR34 CR35 CR36\" citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e]\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eIn recent years, increasing evidence has suggested that the interaction between tumor cells and platelets is a prerequisite for the successful transmission of blood metastasis\u003csup\u003e[\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]\u003c/sup\u003e. Platelets stimulate the proliferation of cancer cells by releasing a variety of cytokines and chemokines, as well as accelerate tumor angiogenesis through various angiogenic regulatory factors, thereby playing a crucial role in the growth and metastasis of cancer cells\u003csup\u003e[\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e]\u003c/sup\u003e. Zhang et al. demonstrated that cancer cells can be reprogrammed to a metastatic state by acquiring platelet mitochondria via the PINK1/Parkin-Mfn2 signaling pathway. In addition, platelet mitochondria regulate the GSH/GSSG ratio and reactive oxygen species of tumor cells, promoting lung metastasis of osteosarcoma\u003csup\u003e[\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e]\u003c/sup\u003e. Neutrophils are the most abundant myeloid cells in human blood and are important regulators of cancer\u003csup\u003e[\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e]\u003c/sup\u003e. External stimulation of the tumor microenvironment can trigger the accumulation of tumor-associated neutrophils in local areas and switch between anti-tumor and pro-tumor phenotypes\u003csup\u003e[\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e]\u003c/sup\u003e. Anti-tumor neutrophils kill tumor cells directly through cytotoxic effects, as well as indirectly through the activation of adaptive immune responses. In contrast, the pro-tumor phenotype of neutrophils may be related to cell proliferation, angiogenesis, and immunosuppression in the tumor microenvironment\u003csup\u003e[\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e]\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eThere are several limitations associated with the analytical process of this retrospective study. First, subjectivity in the collection of CRC patient data may have contributed to biases in our findings. Secondly, the influencing factors included in our study are not comprehensive. Third, this retrospective study is a single-center study that includes a relatively small number of patients, which may affect the accuracy of our results. Future studies that incorporate more patients from multiple centers and a comprehensive risk factor analysis are the next step to carry out survival and related risk factor analyses of CRC patients to better serve clinicians and patients.\u003c/p\u003e"},{"header":"5. Conclusion","content":"\u003cp\u003eThe PNI is a simple and feasible indicator for predicting CRC, and can therefore be used as an effective prognostic indicator for postoperative survival, which will benefit clinicians in their decision making processes regarding individual patient treatment strategies and medication plans.\u003c/p\u003e"},{"header":"Declarations","content":"\u003ch2\u003eData availability statement\u003c/h2\u003e\n\u003cp\u003eThe raw data supporting the findings of this study will be made available by the authors without undue reservation.\u003c/p\u003e\n\u003ch2\u003eEthics statement\u003c/h2\u003e\n\u003cp\u003eThis study involving human participants was approved by the Medical Ethics Committee of the Taizhou People\u0026apos;s Hospital Affiliated to Nanjing Medical University (Taizhou, China). The ethics committee waived the requirement for informed consent from patients.\u003c/p\u003e\n\u003ch2\u003eConflict of interest statement\u003c/h2\u003e\n\u003cp\u003eThe authors declare that they have no conflicts of interest.\u003c/p\u003e\n\u003ch2\u003eFunding sources\u003c/h2\u003e\n\u003cp\u003eThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.\u003c/p\u003e\n\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\n\u003cp\u003eHGQ and QYZ conceived and designed the experiments and supervised the study. SFF collected the data. WS and JFW analysed and interpreted the data. BJ and SZ applied for approval of ethics. HFL wrote the manuscript and supervised the study. All authors read and approved the final manuscript for publication.\u003c/p\u003e\n\u003ch2\u003eAcknowledgements\u003c/h2\u003e\n\u003cp\u003eWe appreciate the data collectors, supervisors, and study participants for their courtesy and cooperation, without whom the study would not have been possible to complete the entire data collection process. We alao thank International Science Editing (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://www.internationalscienceediting.com\u003c/span\u003e\u003c/span\u003e) for editing this manuscript.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eLannagan TR, Jackstadt R, Leedham SJ, et al. Advances in colon cancer research: in vitro and animal models[J]. Curr Opin Genet Dev. 2021;66:50\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eColon Cancer[J]. Am Fam Physician. 2018;97(10):Online.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin. 2021;71(3):209\u0026ndash;49.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBaidoun F, Elshiwy K, Elkeraie Y, et al. Colorectal Cancer Epidemiology: Recent Trends and Impact on Outcomes[J]. Curr Drug Targets. 2021;22(9):998\u0026ndash;1009.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSu Y, Yuan Y, Feng S, et al. High frequency stimulation induces sonic hedgehog release from hippocampal neurons[J]. Sci Rep. 2017;7:43865.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBreakwell GM. Are you stressed out?[J]. Am J Nurs. 1990;90(8):31\u0026ndash;3.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBai X, Wei H, Liu W, et al. Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites[J]. Gut. 2022;71(12):2439\u0026ndash;50.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMotsuku L, Chen WC, Muchengeti MM, et al. Colorectal cancer incidence and mortality trends by sex and population group in South Africa: 2002\u0026ndash;2014[J]. BMC Cancer. 2021;21(1):129.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBradbury KE, Murphy N, Key TJ. Diet and colorectal cancer in UK Biobank: a prospective study[J]. Int J Epidemiol. 2020;49(1):246\u0026ndash;58.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBardou M, Barkun AN, Martel M. Obesity and colorectal cancer[J]. Gut. 2013;62(6):933\u0026ndash;47.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMohri Y, Inoue Y, Tanaka K, et al. Prognostic nutritional index predicts postoperative outcome in colorectal cancer[J]. World J Surg. 2013;37(11):2688\u0026ndash;92.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShen F, Ma Y, Guo W, et al. Prognostic Value of Geriatric Nutritional Risk Index for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis[J]. Lung. 2022;200(5):661\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIshiguro T, Aoyama T, Ju M, et al. Prognostic Nutritional Index as a Predictor of Prognosis in Postoperative Patients With Gastric Cancer[J]. Vivo. 2023;37(3):1290\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang L, Ma W, Qiu Z, et al. Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors[J]. Front Immunol. 2023;14:1219929.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHuang H, Liu Q, Zhu L, et al. Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Patients with Cervical Cancer[J]. Sci Rep. 2019;9(1):3284.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma[J]. Clin Cancer Res. 2014;20(23):6212\u0026ndash;22.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHe L, Xie X, Xue J, et al. Association of the systemic immune-inflammation index with all-cause mortality in patients with arteriosclerotic cardiovascular disease[J]. Front Cardiovasc Med. 2022;9:952953.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiu B, Wang J, Li YY, et al. The association between systemic immune-inflammation index and rheumatoid arthritis: evidence from NHANES 1999\u0026ndash;2018[J]. Arthritis Res Ther. 2023;25(1):34.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXie R, Liu X, Wu H, et al. Associations between systemic immune-inflammation index and abdominal aortic calcification: Results of a nationwide survey[J]. Nutr Metab Cardiovasc Dis. 2023;33(7):1437\u0026ndash;43.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eUshigome M, Shimada H, Miura Y, et al. Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA[J]. Int J Clin Oncol. 2020;25(4):622\u0026ndash;32.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiu JM, Wang YY, Liu W, et al. Preoperative CA19-9: a competitive predictor of recurrence in patients with colorectal cancer liver metastases after hepatectomy[J]. Int J Colorectal Dis. 2021;36(4):767\u0026ndash;78.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGalli C, Basso D, Plebani M. CA 19\u0026thinsp;\u0026ndash;\u0026thinsp;9: handle with care[J]. Clin Chem Lab Med. 2013;51(7):1369\u0026ndash;83.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYu D, An G, Yao J. Lymphocyte-to-monocyte ratio combined with CA19-9 for predicting postoperative recurrence of colorectal cancer in patients with diabetes[J]. J Clin Lab Anal. 2021;35(9):e23944.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGiannakis M, Mu XJ, Shukla SA, et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma[J]. Cell Rep. 2016;15(4):857\u0026ndash;65.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang C, Liu J, Xu D, et al. Gain-of-function mutant p53 in cancer progression and therapy[J]. J Mol Cell Biol. 2020;12(9):674\u0026ndash;87.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKubota K, Ito R, Narita N, et al. Utility of prognostic nutritional index and systemic immune-inflammation index in oral cancer treatment[J]. BMC Cancer. 2022;22(1):368.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRudnik-Jansen I, Howard KA. FcRn expression in cancer: Mechanistic basis and therapeutic opportunities[J]. J Control Release. 2021;337:248\u0026ndash;57.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJeng LB, Chan WL, Teng CF. Prognostic Significance of Serum Albumin Level and Albumin-Based Mono- and Combination Biomarkers in Patients with Hepatocellular Carcinoma[J]. Cancers (Basel), 2023,15(4).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePaul M, Itoo AM, Ghosh B, et al. Current trends in the use of human serum albumin for drug delivery in cancer[J]. Expert Opin Drug Deliv. 2022;19(11):1449\u0026ndash;70.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang Z, Wang Y, Zhang X, et al. Pretreatment prognostic nutritional index as a prognostic factor in lung cancer: Review and meta-analysis[J]. Clin Chim Acta. 2018;486:303\u0026ndash;10.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang X, Liu Y, Mu D. Influence of Prognostic Nutritional Index on the Surveillance After Surgery-Based Systematic Therapy for Breast Cancer[J]. Am Surg. 2023;89(12):6157\u0026ndash;71.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi J, Cao D, Huang Y, et al. The Prognostic and Clinicopathological Significance of Systemic Immune-Inflammation Index in Bladder Cancer[J]. Front Immunol. 2022;13:865643.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMahemuti N, Jing X, Zhang N et al. Association between Systemic Immunity-Inflammation Index and Hyperlipidemia: A Population-Based Study from the NHANES (2015\u0026ndash;2020)[J]. Nutrients, 2023,15(5).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eThakur S, Dhapola R, Sarma P, et al. Neuroinflammation in Alzheimer's Disease: Current Progress in Molecular Signaling and Therapeutics[J]. Inflammation. 2023;46(1):1\u0026ndash;17.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGuo W, Song Y, Sun Y, et al. Systemic immune-inflammation index is associated with diabetic kidney disease in Type 2 diabetes mellitus patients: Evidence from NHANES 2011\u0026ndash;2018[J]. Front Endocrinol (Lausanne). 2022;13:1071465.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSong Y, Guo W, Li Z, et al. Systemic immune-inflammation index is associated with hepatic steatosis: Evidence from NHANES 2015\u0026ndash;2018[J]. Front Immunol. 2022;13:1058779.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang RH, Wen WX, Jiang ZP, et al. The clinical value of neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR) and systemic inflammation response index (SIRI) for predicting the occurrence and severity of pneumonia in patients with intracerebral hemorrhage[J]. Front Immunol. 2023;14:1115031.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGeranpayehvaghei M, Dabirmanesh B, Khaledi M, et al. Cancer-associated-platelet-inspired nanomedicines for cancer therapy[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021;13(5):e1702.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSabrkhany S, Kuijpers M, Oude EM, et al. Platelets as messengers of early-stage cancer[J]. Cancer Metastasis Rev. 2021;40(2):563\u0026ndash;73.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang W, Zhou H, Li H, et al. Cancer cells reprogram to metastatic state through the acquisition of platelet mitochondria[J]. Cell Rep. 2023;42(9):113147.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHedrick CC, Malanchi I. Neutrophils in cancer: heterogeneous and multifaceted[J]. Nat Rev Immunol. 2022;22(3):173\u0026ndash;87.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAdrover JM, McDowell S, He XY, et al. NETworking with cancer: The bidirectional interplay between cancer and neutrophil extracellular traps[J]. Cancer Cell. 2023;41(3):505\u0026ndash;26.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eQue H, Fu Q, Lan T, et al. Tumor-associated neutrophils and neutrophil-targeted cancer therapies[J]. Biochim Biophys Acta Rev Cancer. 2022;1877(5):188762.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003eTables 1 to 3 are available in the Supplementary Files section.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-cancer","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bcan","sideBox":"Learn more about [BMC Cancer](http://bmccancer.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bcan/default.aspx","title":"BMC Cancer","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"colorectal cancer, systemic immune-inflammation index, prognostic nutritional index, prognosis","lastPublishedDoi":"10.21203/rs.3.rs-4712641/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4712641/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eColorectal cancer (CRC) is a common malignant tumor of the digestive tract. Although many prognostic indicators are currently available, it remains unclear which indicators are the most beneficial for patients with CRC. Therefore, there is a critical need to identify a simple, convenient and accurate prognostic indicator.\u003c/p\u003e\u003ch2\u003ePurpose\u003c/h2\u003e \u003cp\u003eTo investigate the clinical significance of the systemic immune-inflammation index (SII) and prognostic nutritional index (PNI) as prognostic indicators for the survival of patients with CRC.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eThe clinical data of CRC patients admitted to the general surgery ward of Taizhou People's Hospital affiliated to Nanjing Medical University from January 2015 to January 2018 were retrospectively analyzed. Two prognostic indicators (SII and PNI) were compared to evaluate their prognostic value in CRC patients.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eBased on these variables, we constructed a LASSO prediction model. The AUC value and 95% CI of the training group were 0.917 (0.858\u0026ndash;0.976) compared to 0.932 (0.846\u0026ndash;1.000) in the validation group. We found that CEA\u0026thinsp;\u0026gt;\u0026thinsp;5 ng/mL, tumor stage, pathological type, postoperative complications, and PNI were associated with the five-year survival rate of CRC patients. Receiver Operating Characteristic Curves (ROC) were drawn to assess the prediction accuracy of the model. The AUC and 95% CI of the training group were 0.913 (0.854\u0026ndash;0.972), while the AUC and 95% CI of the validation group were 0.954 (0.899\u0026ndash;1.000).\u003c/p\u003e\u003ch2\u003eConclusions\u003c/h2\u003e \u003cp\u003ePNI is an independent risk factor for postoperative complications associated with CRC and a powerful tool for predicting survival outcomes in CRC patients.\u003c/p\u003e","manuscriptTitle":"Prognostic value of the preoperative prognostic nutritional and systemic immunoinflammatory indexes in patients with colorectal cancer","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-08-09 21:14:30","doi":"10.21203/rs.3.rs-4712641/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2025-02-11T20:13:17+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-02-11T19:56:30+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"112643072880970760941223598954089785555","date":"2025-02-11T19:24:46+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"60647503250649853122708045218765121617","date":"2025-02-11T18:55:59+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"193482958176405634819452767773216891984","date":"2025-01-22T20:42:36+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-01-21T13:41:35+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"216839287863948079217111791606777852362","date":"2025-01-21T13:37:00+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"183641195627415437459550307647822721109","date":"2025-01-20T08:32:20+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"81628351808025875228296343736194430461","date":"2025-01-19T20:20:46+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"121737439310707988016419893204578261679","date":"2025-01-17T23:10:17+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"11938282886996284718628096709862307200","date":"2025-01-17T19:45:35+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"160551376480874930248855982193311379633","date":"2025-01-17T18:50:07+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2024-08-17T11:26:41+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2024-07-12T14:06:00+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-07-10T07:13:35+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-07-10T07:12:24+00:00","index":"","fulltext":""},{"type":"submitted","content":"BMC Cancer","date":"2024-07-09T14:02:43+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-cancer","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bcan","sideBox":"Learn more about [BMC Cancer](http://bmccancer.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bcan/default.aspx","title":"BMC Cancer","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"1f559dc6-11c2-4302-a2d5-b5e51cd6eeaa","owner":[],"postedDate":"August 9th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2025-03-10T19:48:17+00:00","versionOfRecord":{"articleIdentity":"rs-4712641","link":"https://doi.org/10.1186/s12885-025-13828-3","journal":{"identity":"bmc-cancer","isVorOnly":false,"title":"BMC Cancer"},"publishedOn":"2025-03-05 15:58:43","publishedOnDateReadable":"March 5th, 2025"},"versionCreatedAt":"2024-08-09 21:14:30","video":"","vorDoi":"10.1186/s12885-025-13828-3","vorDoiUrl":"https://doi.org/10.1186/s12885-025-13828-3","workflowStages":[]},"version":"v1","identity":"rs-4712641","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4712641","identity":"rs-4712641","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}